Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.
Despite significant improvements in systemic chemotherapy during the past two decades, the prognosis of patients with advanced gastric and gastroesophageal junction adenocarcinoma remains poor. Because of molecular heterogeneity, it is essential to classify tumors based on the underlying oncogenic pathways and to develop targeted therapies acting on individual tumors. Unfortunately, although a number of molecular targets have been studied, very few of these agents can be used in a clinical setting. In this review, we summarize the available data on anti-angiogenic agents in advanced/metastatic gastric cancer.
Medical Oncology Unit, University of Siena, Viale Bracci 11, 53100, Siena, Italy. giandomenicoroviello@hotmail.it.
Giandomenico
G
Roviello
Medical Oncology Unit, University of Siena, Viale Bracci 11, 53100, Siena, Italy.
Roberto
R
Petrioli
Unit of General and Minimally Invasive Surgery, Department of Medical, Surgical and Neuroscience, University of Siena, Viale Bracci 11, Siena, 53100, Italy.
Luigi
L
Marano
Unit of General and Minimally Invasive Surgery, Department of Medical, Surgical and Neuroscience, University of Siena, Viale Bracci 11, Siena, 53100, Italy.
Karol
K
Polom
Section of Advanced Surgical Oncology, Department of Medical, Surgical and Neurosciences, University of Siena, Viale Bracci 11, Siena, 53100, Italy.
Daniele
D
Marrelli
Medical Oncology Unit, University of Siena, Viale Bracci 11, 53100, Siena, Italy.
Armando
A
Perrella
Unit of General and Minimally Invasive Surgery, Department of Medical, Surgical and Neuroscience, University of Siena, Viale Bracci 11, Siena, 53100, Italy.
Franco
F
Roviello
D000230:Adenocarcinoma / Q000188:drug therapy; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D004938:Esophageal Neoplasms / Q000188:drug therapy; D004943:Esophagogastric Junction / Q000473:pathology; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D000096662:Ramucirumab
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D014408:Biomarkers, Tumor; D058570:TOR Serine-Threonine Kinases; D042461:Vascular Endothelial Growth Factor A; D000096662:Ramucirumab; C467484:VEGFA protein, human; C546842:MTOR protein, human
Bevacizumab; Gastric cancer; Ramucirumab; VEGF